Queensland biotechnology company Vaxxas has raised $25 million in a Series B funding round, which will be used to advance clinical trials of its innovative technology that could one day lead to the end of the vaccine syringe.
The one piece of advice Xero’s Trent Innes gives small business owners to ensure they survive 
UK investment giant Investec leads a $4 million raise for retail data merging firm Fusion Factory 
The most important thing I learnt working on my startup in an accelerator is knowing that sometimes it’s OK to quit 
KPMG is looking for the 100 best fintechs in the world 
Daily startup news and insights, delivered to your inbox.
![[VIDEO] Go inside KPMG’s Sydney Innovation Lab](https://www.startupdaily.net/wp-content/uploads/2017/09/KPMG-Innovation-Lab-600x300.png)
![[VIDEO] How developer Lend Lease is embracing innovation](https://www.startupdaily.net/wp-content/uploads/2017/07/Lend-Lease-Michael-Vavakis-600x300.png)
